S&P 500
7,535.80
-0.61%
Dow Jones
52,560.30
-0.30%
Nasdaq 100
29,018.00
-1.82%
Russell 2000
2,978.14
-0.11%
FTSE 100
10,575.30
+0.83%
Nikkei 225
65,910.10
-2.63%

Investing

New All-Time High Signals More Strength at Apple (AAPL)

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Apple Inc. (NASDAQ: AAPL) may be criticised for a myriad of issues and it may be praised for a myriad of issues.  Generally speaking, the investing purists wills ay all that matters is the stock price. If the purists are correct, then all is not just well but it is continuing to do even better.  This is a new all-time high in shares of Apple.  After a 0.9% gain the stock’s new high is $457.12.  The prior 52-week trading range is $310.50 to $454.45.

Just yesterday came word from Trefis of a $550 target… Prior to that, we noted two analysts with targets north of $600 per share.

The consensus price target today is $562.96 per Thomson Reuters data.

JON C. OGG

Contact [email protected] for any questions or corrections.

Disclaimer: Energy Exploration Technologies, Inc. ("EnergyX") has engaged 24/7 Wall St to publish this communication in connection with EnergyX's ongoing Regulation A offering. 24/7 Wall St has been paid in cash and may receive additional compensation. 24/7 Wall St and/or its affiliates do not currently hold securities of EnergyX.

This compensation and any current or future ownership interest could create a conflict of interest. Please consider this disclosure alongside EnergyX's offering materials. EnergyX's Regulation A offering has been qualified by the SEC. Offers and sales may be made only by means of the qualified offering circular. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at invest.energyx.com/.

Comparisons to other companies are for informational purposes only and should not imply similar results. Past performance is not indicative of future results. Market shortfall are forward‑looking estimates and are subject to substantial uncertainty. Investments in private placements, and start-up investments in particular, are long-term, illiquid, speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups

Follow 24/7 Wall St. on Google
Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. www.247wallst.com.

Continue Reading

The Good and the Bad in a Qualcomm-Broadcom Merger
Jon C. Ogg |

The Good and the Bad in a Qualcomm-Broadcom Merger

So far, Wall Street likes the thought of this merger. Still, many investors seem remain skeptical about a deal that…

Chris Lange |

Major Insider Buying at GNC: A Key Gamble or a Dream?

GNC Holdings has had a very rough 2014. Recent changes inside the company are trying to rectify the situation. The…

Jon C. Ogg |

UBS Sees Apple Shares Rising to $560

JoeInQueens, via Wikimedia CommonsApple Inc. (NASDAQ: AAPL) already was recovering from its lows when Carl Icahn tweeted that he had purchased a…

Steven M. Peters |

Wedbush: After brutal sell-off, what’s next for Apple?

From a note to clients that landed on my desktop Christmas eve.

Top Analyst Upgrades and Downgrades: AbbVie, Agilent, Albermarle, Apple, Boeing, Cheniere, First Solar, HCA, LabCorp, Lumber Liquidators, Teva and More
Jon C. Ogg |

Top Analyst Upgrades and Downgrades: AbbVie, Agilent, Albermarle, Apple, Boeing, Cheniere, First Solar, HCA, LabCorp, Lumber Liquidators, Teva and More

The top analyst upgrades, downgrades and initiations seen on Thursday included AbbVie, Agilent Technologies, Albermarle, Apple, Boeing, Cheniere Energy, First…

Jon C. Ogg |

8 Massive Summer Stock Buybacks Too Large to Ignore

Corporations are using massive stockpiles of cash to buy back shares in droves in 2018, even as the stock market…

Despite Massive Recovery from Lows, Expectations for Apple Keep Going Lower
Jon C. Ogg |

Despite Massive Recovery from Lows, Expectations for Apple Keep Going Lower

It goes without saying that the instant recession and massive drop in the stock market caught many investors off guard.…

Goldman Sachs Maintains Myriad Genetics Buy Recommendation
247patrick |

Goldman Sachs Maintains Myriad Genetics Buy Recommendation

Goldman Sachs has maintained coverage of Myriad Genetics with a Buy recommendation.

Why Analysts Are Abandoning Myriad Genetics Upside Hopes
Jon C. Ogg |

Why Analysts Are Abandoning Myriad Genetics Upside Hopes

24/7 Wall St. could not help but notice how many analysts on Wall Street have simply abandoned their old upside…

Top Gaining Stocks

Abbott Laboratories
ABT • Vol: 31,301,287
J.B. Hunt Transport Services
JBHT • Vol: 2,469,239
Erie Indemnity
ERIE • Vol: 448,793
Dexcom
DXCM • Vol: 6,635,326
Cintas
CTAS • Vol: 4,242,485

Top Losing Stocks

Seagate Technology
STX • Vol: 6,205,661
Corning
GLW • Vol: 17,617,020
Western Digital
WDC • Vol: 10,512,294
Coterra Energy
CTRA • Vol: 73,319,495
Super Micro Computer
SMCI • Vol: 35,537,269